Long-term efficacy of 6-month therapy with isoniazid and rifampin compared with isoniazid, rifampin, and pyrazinamide treatment for pleural tuberculosis

Research into anti-tuberculosis treatment has mainly focused on pulmonary tuberculosis (TB), with few studies on pleural-TB. The aim of the study is to compare the long-term efficacy of a 6-month treatment regimen with isoniazid and rifampicin (6HR) with treatment regimen of isoniazid, rifampicin, a...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical microbiology & infectious diseases 2019-11, Vol.38 (11), p.2121-2126
Main Authors: García-Rodríguez, José Francisco, Valcarce-Pardeiro, N., Álvarez-Díaz, H., Mariño-Callejo, A.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Antitubercular Agents - adverse effects
Antitubercular Agents - therapeutic use
Biomedical and Life Sciences
Biomedicine
Biopsy
Case-Control Studies
Comparative studies
Demographics
Drug Therapy, Combination
Female
Follow-Up Studies
HIV
Human immunodeficiency virus
Humans
Internal Medicine
Isoniazid
Isoniazid - administration & dosage
Isoniazid - adverse effects
Isoniazid - therapeutic use
Male
Medical Microbiology
Middle Aged
Original Article
Patients
Pleural effusion
Pleural fluid
Pyrazinamide
Pyrazinamide - administration & dosage
Pyrazinamide - adverse effects
Pyrazinamide - therapeutic use
Rifampin
Rifampin - administration & dosage
Rifampin - adverse effects
Rifampin - therapeutic use
Side effects
Spain - epidemiology
Toxicity
Treatment Outcome
Tuberculosis
Tuberculosis, Pleural - drug therapy
Tuberculosis, Pleural - epidemiology
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Research into anti-tuberculosis treatment has mainly focused on pulmonary tuberculosis (TB), with few studies on pleural-TB. The aim of the study is to compare the long-term efficacy of a 6-month treatment regimen with isoniazid and rifampicin (6HR) with treatment regimen of isoniazid, rifampicin, and pyrazinamide (6HR2Z) for pleural-TB. A case-control study of 200 HIV-negative patients with pleural-TB prospectively followed in our TB-unit from 1995 to 2018. The primary resistance to isoniazid is
ISSN:0934-9723
1435-4373
DOI:10.1007/s10096-019-03651-7